Aptose Biosciences Inc. (APTO)
Market Closed
10 Feb, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
1. 71
0
0%
$
4.36M Market Cap
- P/E Ratio
- Div Yield
648,213 Volume
- Eps
$ 1.71
Previous Close 
Want to track APTO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.
Benzinga | 1 year ago
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 2 years ago
